UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
March 13, 2015
Date of report (Date of earliest event reported)
Nexvet Biopharma
public limited company
(Exact Name of Registrant as Specified in Its Charter)
| Ireland | 001-36828 | 98-1205017 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
National Institute for Bioprocessing Research and Training
Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland
(Address of principal executive offices, including Zip Code)
+353 1 215 8100
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02 | Regulation FD Disclosure |
On March 13, 2015, Nexvet Biopharma public limited company (the “Company”) reported its financial results for the second quarter of fiscal year 2015 (the quarterly period ended December 31, 2014). The Company’s earnings release for this period is furnished herewith as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
Exhibit | Description | |
| 99.1 | Earnings release dated March 13, 2015 announcing the Company’s financial results for the second quarter of fiscal year 2015. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Nexvet Biopharma public limited company | ||
| By: | /s/ Mark Heffernan, Ph.D | |
| Name: | Mark Heffernan | |
| Its: | Chief Executive Officer | |
Date: March 13, 2015